Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Approximately 17% of all patients with stroke are classified as having ESUS, which is
associated with a considerable rate of stroke recurrence 4-5 % per year.
Despite recent scientific advances in acute ischemic stroke treatment in recent
decades,consensus treatment of all guidelines is still ASA